Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1800 1
1853 1
1873 1
1875 1
1877 6
1881 1
1885 2
1886 1
1887 3
1888 3
1889 2
1890 3
1891 2
1892 1
1895 2
1896 2
1897 6
1898 3
1900 1
1901 1
1903 1
1904 1
1905 4
1908 2
1909 10
1910 5
1911 14
1912 3
1913 11
1914 3
1915 5
1916 14
1917 8
1918 10
1919 3
1920 4
1921 7
1922 19
1923 29
1924 17
1925 21
1926 13
1927 20
1928 14
1929 21
1930 20
1931 25
1932 26
1933 19
1934 32
1935 36
1936 29
1937 25
1938 32
1939 21
1940 24
1941 10
1942 15
1943 15
1944 16
1945 650
1946 2239
1947 2249
1948 2533
1949 1631
1950 221
1951 2982
1952 6697
1953 8103
1954 8413
1955 9064
1956 9465
1957 10057
1958 9778
1959 10378
1960 11378
1961 12059
1962 8209
1963 6379
1964 15246
1965 20298
1966 27006
1967 32598
1968 36388
1969 39956
1970 42052
1971 45217
1972 48951
1973 52178
1974 55868
1975 56626
1976 56882
1977 57988
1978 60713
1979 64078
1980 65542
1981 67284
1982 71950
1983 75288
1984 78182
1985 80753
1986 82999
1987 86514
1988 93174
1989 100244
1990 105519
1991 105693
1992 106730
1993 108659
1994 111834
1995 115113
1996 115940
1997 117129
1998 119923
1999 122450
2000 130808
2001 138692
2002 146195
2003 154765
2004 160129
2005 170885
2006 180674
2007 188547
2008 196269
2009 203018
2010 216727
2011 232342
2012 241761
2013 248897
2014 254557
2015 259566
2016 256490
2017 258824
2018 265342
2019 270776
2020 276984
2021 267871
2022 249053
2023 220700
2024 91784
2025 1

Text availability

Article attribute

Article type

Publication date

Search Results

7,420,065 results

Results by year

Filters applied: . Clear all
Page 1
Pd-based nanoparticles: Plant-assisted biosynthesis, characterization, mechanism, stability, catalytic and antimicrobial activities.
Nasrollahzadeh M, Sajjadi M, Dadashi J, Ghafuri H. Nasrollahzadeh M, et al. Adv Colloid Interface Sci. 2020 Feb;276:102103. doi: 10.1016/j.cis.2020.102103. Epub 2020 Jan 9. Adv Colloid Interface Sci. 2020. PMID: 31978638 Review.
Among various metal nanoparticles, palladium nanoparticles (Pd NPs) are one of the most important and fascinating nanomaterials. ...This review attempts to cover the recent progresses in the fabrication, characterization and broad applications of biogenic Pd NPs in …
Among various metal nanoparticles, palladium nanoparticles (Pd NPs) are one of the most important and fascinating nanomaterials. ...T …
Emerging targets for anticancer vaccination: PD-1.
Tobias J, Steinberger P, Drinić M, Wiedermann U. Tobias J, et al. ESMO Open. 2021 Oct;6(5):100278. doi: 10.1016/j.esmoop.2021.100278. Epub 2021 Oct 11. ESMO Open. 2021. PMID: 34649221 Free PMC article. Review.
Among the mechanisms by which tumor cells escape the immune surveillance, one is the interaction between programmed cell death protein 1 (PD-1) and its ligand programmed death-ligand 1 (PD-L1). Inhibition of the PD-1/PD-L1 pathway with monoclonal antib …
Among the mechanisms by which tumor cells escape the immune surveillance, one is the interaction between programmed cell death protein 1 ( …
Combination Strategies PD-1/PD-L1 Antagonists.
Sznol M. Sznol M. Cancer J. 2018 Jan/Feb;24(1):54-57. doi: 10.1097/PPO.0000000000000304. Cancer J. 2018. PMID: 29360729 Review.
Despite the broad clinical antitumor activity of PD-1/PD-L1 antagonists, many patients who are treated with these agents either do not respond or achieve suboptimal responses. ...Many combination trials have been initiated in patients with or without prior exposure …
Despite the broad clinical antitumor activity of PD-1/PD-L1 antagonists, many patients who are treated with these agents eithe …
Progress in PD-1/PD-L1 pathway inhibitors: From biomacromolecules to small molecules.
Lin X, Lu X, Luo G, Xiang H. Lin X, et al. Eur J Med Chem. 2020 Jan 15;186:111876. doi: 10.1016/j.ejmech.2019.111876. Epub 2019 Nov 15. Eur J Med Chem. 2020. PMID: 31761384 Review.
However, no small-molecule inhibitors have been approved so far, indicating a challenging process of developing marketable small-molecule PD-1/PD-L1 targeted therapeutics. This review will summarize and provide insight into recent advances in the PD-1/PD …
However, no small-molecule inhibitors have been approved so far, indicating a challenging process of developing marketable small-molecule …
Small Molecules as PD-1/PD-L1 Pathway Modulators for Cancer Immunotherapy.
Jiao P, Geng Q, Jin P, Su G, Teng H, Dong J, Yan B. Jiao P, et al. Curr Pharm Des. 2018;24(41):4911-4920. doi: 10.2174/1381612824666181112114958. Curr Pharm Des. 2018. PMID: 30417781 Review.
Blockade of PD-1/PD-L1 interactions using PD-1/PD-L1 pathway modulators has shown unprecedented clinical efficacy in various cancer models. Current PD-1/PD-L1 modulators approved by FDA are exclusively dominated by therapeutic antibodies. …
Blockade of PD-1/PD-L1 interactions using PD-1/PD-L1 pathway modulators has shown unprecedented clinical efficac …
N6-methyladenosine RNA modification in PD-1/PD-L1: Novel implications for immunotherapy.
Luo P, Li S, Long X. Luo P, et al. Biochim Biophys Acta Rev Cancer. 2023 May;1878(3):188873. doi: 10.1016/j.bbcan.2023.188873. Epub 2023 Feb 24. Biochim Biophys Acta Rev Cancer. 2023. PMID: 36842764 Review.
Therefore, identifying the underlying modulators of the PD-1/PD-L1 pathway to completely comprehend the mechanisms of anti-PD-1/PD-L1 treatment is crucially important. ...We also reviewed m6A-associated lncRNAs in the regulation of the PD-1/P …
Therefore, identifying the underlying modulators of the PD-1/PD-L1 pathway to completely comprehend the mechanisms of anti- …
Research Status and Outlook of PD-1/PD-L1 Inhibitors for Cancer Therapy.
Ai L, Chen J, Yan H, He Q, Luo P, Xu Z, Yang X. Ai L, et al. Drug Des Devel Ther. 2020 Sep 8;14:3625-3649. doi: 10.2147/DDDT.S267433. eCollection 2020. Drug Des Devel Ther. 2020. PMID: 32982171 Free PMC article. Review.
PD-1/PD-L1 inhibitors are a group of immune checkpoint inhibitors as front-line treatment of multiple types of cancer. ...Therefore, it is urgent to develop novel inhibitors, such as small molecules, peptides or macrocycles, targeting the PD-1/PD-L1 ax …
PD-1/PD-L1 inhibitors are a group of immune checkpoint inhibitors as front-line treatment of multiple types of cancer. ...Ther …
Advances of biphenyl small-molecule inhibitors targeting PD-1/PD-L1 interaction in cancer immunotherapy.
Chen R, Yuan D, Ma J. Chen R, et al. Future Med Chem. 2022 Jan;14(2):97-113. doi: 10.4155/fmc-2021-0256. Epub 2021 Dec 6. Future Med Chem. 2022. PMID: 34870447 Review.
Immunotherapy inhibiting the programmed death-1/programmed death ligand-1 (PD-1/PD-L1) interaction has emerged as one of the most attractive cancer treatment strategies. ...The development of small-molecule inhibitors targeting PD-1/PD-L1 interaction i …
Immunotherapy inhibiting the programmed death-1/programmed death ligand-1 (PD-1/PD-L1) interaction has emerged as one of the m …
PD-L1 induces macrophage polarization toward the M2 phenotype via Erk/Akt/mTOR.
Wei Y, Liang M, Xiong L, Su N, Gao X, Jiang Z. Wei Y, et al. Exp Cell Res. 2021 May 15;402(2):112575. doi: 10.1016/j.yexcr.2021.112575. Epub 2021 Mar 24. Exp Cell Res. 2021. PMID: 33771483
It is well known that PD-L1 suppresses T cell function via binding to PD-1. However, little is known about the role of the PD-1/PD-L1 axis in macrophage polarization. ...Thus, we treated THP-1-derived macrophages with human PD-L1 Fc to determine …
It is well known that PD-L1 suppresses T cell function via binding to PD-1. However, little is known about the role of the …
Protein homodimer sequestration with small molecules: Focus on PD-L1.
Bailly C, Vergoten G. Bailly C, et al. Biochem Pharmacol. 2020 Apr;174:113821. doi: 10.1016/j.bcp.2020.113821. Epub 2020 Jan 20. Biochem Pharmacol. 2020. PMID: 31972166 Review.
Monoclonal antibodies targeting the PD-1/PD-L1 immune checkpoint have emerged as efficient cancer biotherapeutics. ...Drug-induced sequestration of PD-L1 homodimers prevents binding of PD-L1 to PD-1, thus blocking the downstream signaling. ...
Monoclonal antibodies targeting the PD-1/PD-L1 immune checkpoint have emerged as efficient cancer biotherapeutics. ...Drug-ind …
7,420,065 results
You have reached the last available page of results. Please see the User Guide for more information.